These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 20347657)

  • 21. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
    Van Doorslaer EK; Tormans G; Gupta AK; Van Rossem K; Eggleston A; Dubois DJ; De Doncker P; Haneke E
    Dermatology; 1996; 193(3):239-44. PubMed ID: 8944348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis.
    Bueno JG; Martinez C; Zapata B; Sanclemente G; Gallego M; Mesa AC
    Clin Exp Dermatol; 2010 Aug; 35(6):658-63. PubMed ID: 19874354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onychomycosis: modern diagnostic and treatment approaches.
    Tchernev G; Penev PK; Nenoff P; Zisova LG; Cardoso JC; Taneva T; Ginter-Hanselmayer G; Ananiev J; Gulubova M; Hristova R; Nocheva D; Guarneri C; Martino G; Kanazawa N
    Wien Med Wochenschr; 2013 Jan; 163(1-2):1-12. PubMed ID: 23053563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
    Gupta AK; Konnikov N; Lynde CW
    J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onychomycosis in the elderly : drug treatment options.
    Loo DS
    Drugs Aging; 2007; 24(4):293-302. PubMed ID: 17432924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up.
    Tosti A; Piraccini BM; Stinchi C; Colombo MD
    Dermatology; 1998; 197(2):162-6. PubMed ID: 9732167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of antifungal agents in onychomycoses.
    Debruyne D; Coquerel A
    Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
    Gupta AK; Lambert J
    Int J Dermatol; 1999 Sep; 38 Suppl 2():53-64. PubMed ID: 10515529
    [No Abstract]   [Full Text] [Related]  

  • 29. [Onychomycosis is rare in young children, and treatment is a task for dermatological specialists].
    Haugaard LK; Skov L; Arendrup MC; Saunte DM
    Ugeskr Laeger; 2013 Sep; 175(40):2343-4. PubMed ID: 24079324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toenail onychomycosis by Trichophyton rubrum and concurrent infestation with Tyrophagus putrescentiae.
    Fabrizi V; Zacconi I; Principato M; Pesca C; Cruciani D; Crotti S; Papini M
    Infez Med; 2017 Dec; 25(4):377-380. PubMed ID: 29286021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of topical therapies to treat onychomycosis.
    Gupta AK; Ryder JE; Baran R
    Dermatol Clin; 2003 Jul; 21(3):481-9. PubMed ID: 12956200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies.
    Mulvaney PM; Telang GH; Jellinek N
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases.
    Ranawaka RR; Nagahawatte A; Gunasekara TA
    Int J Dermatol; 2015 Nov; 54(11):1275-82. PubMed ID: 26223159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction.
    Stein Gold LF; Rosen T
    Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S47. PubMed ID: 27096143
    [No Abstract]   [Full Text] [Related]  

  • 35. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients.
    De Doncker PR; Scher RK; Baran RL; Decroix J; Degreef HJ; Roseeuw DI; Havu V; Rosen T; Gupta AK; Piérard GE
    J Am Acad Dermatol; 1997 Feb; 36(2 Pt 1):173-7. PubMed ID: 9039163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents.
    Piraccini BM; Sisti A; Tosti A
    J Am Acad Dermatol; 2010 Mar; 62(3):411-4. PubMed ID: 20159308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Onychomycosis.
    Zaraa I; Dehavay F; Richert B
    Hand Surg Rehabil; 2024 Apr; 43S():101638. PubMed ID: 38218374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onychomycosis--treatment, relapse and re-infection.
    Hull PR
    Dermatology; 1997; 194 Suppl 1():7-9. PubMed ID: 9154393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review.
    Evans EG
    J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S32-36. PubMed ID: 9594934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciclopirox nail lacquer solution 8% in the 21st century.
    Gupta AK; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.